Albion News

The UCL Technology Fund (UCLTF), UK Innovation & Science Seed Fund (UKI2S), alongside support from Innovate UK, have invested in UCL spinout company Glialign Ltd, which is developing a novel cell therapy for peripheral nerve repair.  Hundreds of thousands of people every year are affected by severe peripheral nerve damage, resulting in paralysis and loss of sensation, often accompanied by chronic pain. Current therapies are successful in fewer than half of cases and often require grafting of a nerve from another part of the body.  Dr James Phillips, UCL School of Pharmacy, and his team at... read more
Grapeshot
  We are delighted to announce that Oracle Corporation (NYSE: ORCL) has completed the acquisition of Grapeshot Limited. Since 2014, the Albion VCTs have invested a total of £2.9m in the business and on the assumption that the full escrow is received, the exit  represents a return of c.10x for the Albion VCTs.     Grapeshot provides brand safety and pre-bid contextual solutions to over 5,000 of the world’s leading marketers. Each month, over 38 billion programmatic ad impressions are enhanced using Grapeshot’s Contextual Intelligence Platform in dozens of languages, and Grapeshot has grown... read more
Albion Capital, the leading independent investment manager, has led a £6.5 million Series A investment round in PayAsUGym (‘PAUG’), the online fitness marketplace, alongside existing co-investor Concentric and individual angels. The investment will be used to build the team, further enhance the product, grow the gym network and overall user base. PAUG enables gym users to access a national network of thousands of health and fitness clubs, pools, classes and spas, on a flexible pay-as-you-go, short-term pass or unlimited membership basis. The company has rapidly expanded its range of venues... read more
Orchard Therapeutics
  - Agreement strengthens Orchard’s position as a global leader in gene therapy for rare diseases - GSK takes 19.9% equity stake in Orchard and seat on board   GSK and Orchard Therapeutics today announced a strategic agreement, under which GSK will transfer its portfolio of approved and investigational rare disease gene therapies to Orchard, securing the continued development of the programmes and access for patients. This acquisition strengthens Orchard’s position as a global leader in gene therapy for rare diseases. GSK will continue to invest in the development of its platform capabilities... read more
Social Impact Investing
Twenty-two leading financial services companies have so far pledged their commitment to help create a culture of social impact investing in the UK. The signatories which include Albion have pledged to work together to drive forward the key recommendations of the Advisory Group to Government on Social Impact investing. Earlier this month, The Prime Minister, Theresa May, asked Elizabeth Corley, vice chair of Allianz Global Investors, to lead an industry taskforce to progress the Advisory Group’s recommendations. The statement of support asked industry leaders to commit to specific goals... read more
Summary
We are pleased to report that in aggregate £32 million was raised being the full amount targeted by the five participating Albion VCTs.  The Albion VCTs Prospectus Top Up Offers 2017/2018 are now all closed.  We have been delighted by the strong support from new and existing shareholders and their advsers.  Unfulfilled application forms will be returned to the applicant and we will notify their adviser.    For further information please contact us directly on 020 7601 1850.  read more
Peter Evans of the Sunday Times has featured UCL Technology Fund in an article about the need to support Britian's academics to commercialise on their ideas. He discussed how the work of the UCL Technology Fund is vital to stop the loss of 'great British ideas' to foreign companies.  Read the full article here (subscription necessary)  read more
Securities Note
We have closed our 2017/2018 VCT top up offers after successfully raising the £32m amount targeted. The offers, which launched on 6 September 2017, are fully subscribed across the five Albion VCTs participating in the fundraising. We will now focus on investing the money raised in technology-driven, high growth companies, with a particular emphasis on its sector specialisms in digital healthcare, automation, digital security and data analytics. Albion has expanded its presence in the technology sector significantly in recent years, with notable investments including Black Swan Data (... read more
Albion has added three new recruits to its technology team as part of its strategic expansion in the sector. Catriona McDonald and Nadine Torbey have joined the firm to help with tech investments from Albion’s VCT portfolios. Tanel Ozdemir has also joined the investment team at Albion Capital as an analyst on the UCL Technology Fund. The hires support the evolution of Albion’s investment strategy towards a greater focus on growth and innovation, and will enable it to seek more opportunities in its specialisms, including data analytics, cybersecurity, digital health, automation and martech.... read more
The UCL Technology Fund has invested in MediaGamma, the predictive analytics software company, as part of a £2m round in partnership with ParkWalk Advisors and the London Co-Investment Fund (LCIF). MediaGamma has developed a world leading enterprise-grade reinforcement machine learning (self-learning) platform, delivering decisions in under five milliseconds. It has proven its technology in programmatic advertising, building and training more accurate user-profiling and bidding algorithms that vastly reduce customer acquisition costs for their clients. The investment will enable MediaGamma to... read more

Pages